The drug Teflaro, also known as ceftaroline fosamil, is a antibiotic medication used to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is developed and marketed by the pharmaceutical company AbbVie.

As of the information available, the patent expiration date for Teflaro (ceftaroline fosamil) is not explicitly stated. However, according to DrugPatentWatch.com, the patent for the formulation of Teflaro expired in March 2020 [1]. After a patent expires, other companies can apply to the FDA for approval to manufacture and sell generic versions of the drug. However, it's important to note that there may be other patents related to the drug or its manufacturing process that could extend the period of exclusivity for AbbVie.

In summary, based on the available information, the patent for the formulation of Teflaro expired in March 2020 [1]. However, it's important to note that there may be other patents related to the drug or its manufacturing process that could extend the period of exclusivity for AbbVie.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/teflaro>